Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7471015 - Test-Negative Study of 20-valent Pneumococcal Conjugate Vaccine in Adults ≥65 Years
2023-507293-40-00Phase 4Authorised
- Sponsor
- Pfizer
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, open-label trial of Streptococcus pneumoniae type 19A capsular polysaccharide antigen in community-acquired pneumonia (CAP) (2 arms), sponsored by Pfizer. Planned start Mar 2024; status: authorised.
02
Drugs
Streptococcus pneumoniae type 19A capsular polysaccharide antigen
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2023-507293-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507293-40-00.